Agilent Technologies Inc. (NYSE: A) today announced that it has completed the acquisition of ProZyme, Inc., a leading provider of glycan reagents, kits and standards. This acquisition expands Agilent's portfolio of biopharma consumables.

Founded in 1990, Hayward-Calif. based ProZyme is an industry leading developer and manufacturer of glycan reagents, kits and standards, which are required for efficient sample prep in the analysis of free glycans. Glycobiology is one of the fastest-growing segments in biopharma, as glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.

The acquisition of ProZyme follows the recent acquisition of Ultra Scientific, a leading provider of chemical standards and certified reference materials.

"These acquisitions both support Agilent's long-term strategy to provide customers with more workflow-specific consumables and solutions to help them achieve economic, operational and scientific success," said Padraig McDonnell, vice president and general manager of Agilent's Chemistries and Supplies Division.

"We are excited to be adding the ProZyme team and technology to our capabilities," he continued. "Together we can accelerate the development of the solutions our customers need to advance their biopharma research."

Financial terms of the deal are not being disclosed.

More information on ProZyme products and solutions is available at